The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | HMA in combination with venetoclax and magrolimab in the treatment of AML
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, highlights some interesting data from a Phase II study investigating the use of hypomethylating agent (HMA) plus venetoclax and magrolimab in the treatment of both frontline acute myeloid leukemia (AML) patients, as well as relapsed/refractory (R/R) AML patients (NCT04778410). Dr Sallman discusses some of the results from this promising study, drawing focus on p53-mutated patients and the early responses observed. To conclude, Dr Sallman introduces another Phase III trial, ENHANCE-3, which will investigate triplet therapy versus the HMA plus venetoclax doublet therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
